Majerciak V, Zheng Z
Hlife. 2025; 3(1):21-37.
PMID: 40078969
PMC: 11902918.
DOI: 10.1016/j.hlife.2024.11.005.
Maeda T, Ono M, Osako T, Chiba T, Baba S, Iesato A
Cancer Med. 2025; 14(4):e70666.
PMID: 39967410
PMC: 11836529.
DOI: 10.1002/cam4.70666.
Drzyzga A, Czapla J, Matuszczak S, Lasut-Szyszka B, Cichon T, Pilny E
Cancers (Basel). 2025; 17(2.
PMID: 39857957
PMC: 11763682.
DOI: 10.3390/cancers17020175.
Wu J, Chen Y, Xie M, Yu X, Su C
Chin Med J Pulm Crit Care Med. 2025; 2(4):257-264.
PMID: 39834588
PMC: 11742360.
DOI: 10.1016/j.pccm.2024.11.001.
Lu Y, Li Z, Zhu X, Zeng Q, Liu S, Guan W
Int J Nanomedicine. 2025; 20():181-197.
PMID: 39802380
PMC: 11721825.
DOI: 10.2147/IJN.S503780.
Regulation of cGAS-STING signalling and its diversity of cellular outcomes.
Zhang Z, Zhang C
Nat Rev Immunol. 2025; .
PMID: 39774812
DOI: 10.1038/s41577-024-01112-7.
Structures of ATP-binding cassette transporter ABCC1 reveal the molecular basis of cyclic dinucleotide cGAMP export.
Shinde O, Boyer J, Cambier S, VanPortfliet J, Sui X, Yadav G
Immunity. 2025; 58(1):59-73.e5.
PMID: 39765229
PMC: 11735300.
DOI: 10.1016/j.immuni.2024.12.002.
Elucidating the expression and role of cGAS in pan-cancer using integrated bioinformatics and experimental approaches.
Lian Z, Liu X, Li X
BMC Cancer. 2025; 25(1):5.
PMID: 39748320
PMC: 11697830.
DOI: 10.1186/s12885-024-13379-z.
A STING agonist prodrug reprograms tumor-associated macrophage to boost colorectal cancer immunotherapy.
Deng A, Fan R, Hai Y, Zhuang J, Zhang B, Lu X
Theranostics. 2025; 15(1):277-299.
PMID: 39744236
PMC: 11667223.
DOI: 10.7150/thno.101001.
Prospects for potential therapy targeting immune‑associated factors in endometriosis (Review).
Zhang W, Li K, Jian A, Zhang G, Zhang X
Mol Med Rep. 2024; 31(3.
PMID: 39717957
PMC: 11715623.
DOI: 10.3892/mmr.2024.13422.
Discovery of a non-nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect.
Wang X, Zhan Z, Wang Z, Zhang Y, Zhao K, Li H
MedComm (2020). 2024; 6(1):e70001.
PMID: 39712456
PMC: 11661907.
DOI: 10.1002/mco2.70001.
Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform 'cold' tumors into 'hot' tumors.
Ying X, Chen Q, Yang Y, Wu Z, Zeng W, Miao C
Mol Cancer. 2024; 23(1):277.
PMID: 39710707
PMC: 11664935.
DOI: 10.1186/s12943-024-02186-6.
Fantastic proteins and where to find them - histones, in the nucleus and beyond.
Grinat J, Shriever N, Christophorou M
J Cell Sci. 2024; 137(24).
PMID: 39704565
PMC: 11827605.
DOI: 10.1242/jcs.262071.
Cytosolic bacterial pathogens activate TLR pathways in tumors that synergistically enhance STING agonist cancer therapies.
Danielson M, Nicolai C, Vo T, Wolf N, Burke T
iScience. 2024; 27(12):111385.
PMID: 39669426
PMC: 11635009.
DOI: 10.1016/j.isci.2024.111385.
Sequential Release HydroLipo System for STING Gene Epigenetic Reprogramming and Immune Activation in Glioblastoma.
Yu H, Liu W, Ding K, Wu J, Wang C, Wang S
Adv Sci (Weinh). 2024; 12(5):e2408323.
PMID: 39661716
PMC: 11792002.
DOI: 10.1002/advs.202408323.
γδ T Cell-mediated Tumor Immunity is Tightly Regulated by STING and TGF-β Signaling Pathways.
Luo J, Wang S, Yang Q, Fu Q, Zhu C, Li T
Adv Sci (Weinh). 2024; 12(2):e2404432.
PMID: 39573933
PMC: 11727375.
DOI: 10.1002/advs.202404432.
Genomic instability as a driver and suppressor of anti-tumor immunity.
Requesens M, Foijer F, Nijman H, de Bruyn M
Front Immunol. 2024; 15:1462496.
PMID: 39544936
PMC: 11562473.
DOI: 10.3389/fimmu.2024.1462496.
Low-Intensity Focused Ultrasound-Responsive Phase-Transitional Liposomes Loaded with STING Agonist Enhances Immune Activation for Breast Cancer Immunotherapy.
Hu C, Jiang Y, Chen Y, Wang Y, Wu Z, Zhang Q
Cancers (Basel). 2024; 16(21).
PMID: 39518096
PMC: 11545222.
DOI: 10.3390/cancers16213657.
Targeting STING signaling for the optimal cancer immunotherapy.
Xu Y, Xiong Y
Front Immunol. 2024; 15:1482738.
PMID: 39450170
PMC: 11500076.
DOI: 10.3389/fimmu.2024.1482738.
SMAD4 enhances the cytotoxic efficacy of human NK cells against colorectal cancer cells via the mA reader YTHDF2.
Li X, Wang Y, Cai L, Huang S
Front Immunol. 2024; 15:1440308.
PMID: 39439794
PMC: 11494605.
DOI: 10.3389/fimmu.2024.1440308.